Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$33.00
-1.10-3.23%
At close: -
$33.00
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Monopar Therapeutics Analyst Ratings and Price Targets | NASDAQ:MNPR | Benzinga
Monopar Therapeutics Inc has a consensus price target of $39.29 based on the ratings of 9 analysts. The high is $76 issued by Piper Sandler on March 19, 2025. The low is $2 issued by JonesTrading on April 11, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co. on April 1, 2025, March 19, 2025, and January 22, 2025, respectively. With an average price target of $52 between HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co., there's an implied 57.58% upside for Monopar Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Piper Sandler
Rodman & Renshaw
JonesTrading
1calculated from analyst ratings
Analyst Ratings for Monopar Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | — | Jones Trading | Justin Walsh41% | — | Downgrade | Buy → Hold | Get Alert |
| 04/01/2025 | Buy Now | 21.21% | HC Wainwright & Co. | Sean Lee62% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2025 | Buy Now | 130.3% | Piper Sandler | Biren Amin40% | → $76 | Assumes | → Overweight | Get Alert |
| 01/22/2025 | Buy Now | 21.21% | HC Wainwright & Co. | Sean Lee62% | $22 → $40 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 118.18% | Piper Sandler | Christopher Raymond55% | → $72 | Initiates | → Overweight | Get Alert |
| 11/11/2024 | Buy Now | -33.33% | HC Wainwright & Co. | Sean Lee62% | $6 → $22 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | 51.52% | Rodman & Renshaw | Elemer Piros53% | → $50 | Initiates | → Buy | Get Alert |
| 08/14/2024 | Buy Now | -81.82% | HC Wainwright & Co. | Sean Lee62% | $2 → $6 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | -93.94% | HC Wainwright & Co. | Sean Lee62% | $2 → $2 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | -93.94% | JonesTrading | Soumit Roy36% | → $2 | Upgrade | Hold → Buy | Get Alert |
| 06/01/2023 | Buy Now | -48.48% | HC Wainwright & Co. | Sean Lee62% | → $17 | Reiterates | → Buy | Get Alert |
| 05/15/2023 | Buy Now | -93.94% | HC Wainwright & Co. | Sean Lee62% | $6 → $2 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | — | Maxim Group | Jason McCarthy42% | — | Downgrade | Buy → Hold | Get Alert |
| 03/28/2023 | Buy Now | -48.48% | EF Hutton | Elemer Piros53% | $24 → $17 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | -27.27% | EF Hutton | Elemer Piros53% | → $24 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | -81.82% | HC Wainwright & Co. | Sean Lee62% | → $6 | Maintains | Buy | Get Alert |
| 02/14/2023 | Buy Now | -27.27% | EF Hutton | Elemer Piros53% | → $24 | Reiterates | → Buy | Get Alert |
| 01/23/2023 | Buy Now | -27.27% | EF Hutton | Elemer Piros53% | → $24 | Initiates | → Buy | Get Alert |
| 12/09/2022 | Buy Now | -45.45% | Roth Capital | Kumaraguru Raja19% | → $18 | Reinstates | → Buy | Get Alert |
| 08/16/2022 | Buy Now | -81.82% | HC Wainwright & Co. | Sean Lee62% | $9 → $6 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Monopar Therapeutics (MNPR) stock?
The latest price target for Monopar Therapeutics (NASDAQ:MNPR) was reported by Jones Trading on April 2, 2025. The analyst firm set a price target for $0.00 expecting MNPR to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Monopar Therapeutics (MNPR)?
The latest analyst rating for Monopar Therapeutics (NASDAQ:MNPR) was provided by Jones Trading, and Monopar Therapeutics downgraded their hold rating.
When was the last upgrade for Monopar Therapeutics (MNPR)?
The last upgrade for Monopar Therapeutics Inc happened on April 11, 2024 when JonesTrading raised their price target to $2. JonesTrading previously had a hold for Monopar Therapeutics Inc.
When was the last downgrade for Monopar Therapeutics (MNPR)?
The last downgrade for Monopar Therapeutics Inc happened on April 2, 2025 when Jones Trading changed their price target from N/A to N/A for Monopar Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Monopar Therapeutics (MNPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monopar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monopar Therapeutics was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Monopar Therapeutics (MNPR) correct?
While ratings are subjective and will change, the latest Monopar Therapeutics (MNPR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Monopar Therapeutics (MNPR) is trading at is $33.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
